Back to Search
Start Over
Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity.
Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity.
- Source :
- Pharmaceutical Chemistry Journal; Nov2022, Vol. 56 Issue 8, p1024-1026, 3p
- Publication Year :
- 2022
-
Abstract
- The bioavailability of the tablet dosage form of pharmaceutical substance RU-891, i.e., 9-(3,4-dihydroxyphenacyl)-2,3-dihydroimidazo[1,2-a]benzimidazole hydrobromide, was investigated. The main pharmacokinetic parameters were determined. The relative bioavailability index was estimated at 93.98%. No evidence of drug accumulation from an RU-891 270-mg tablet dosage form was detected in rabbits upon threefold administration at a dose of 23 mg/kg. [ABSTRACT FROM AUTHOR]
- Subjects :
- DRUG dosage
BENZIMIDAZOLE derivatives
BIOAVAILABILITY
DOSAGE forms of drugs
Subjects
Details
- Language :
- English
- ISSN :
- 0091150X
- Volume :
- 56
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Pharmaceutical Chemistry Journal
- Publication Type :
- Academic Journal
- Accession number :
- 160372592
- Full Text :
- https://doi.org/10.1007/s11094-022-02746-4